Malignant hyperthermia susceptibility in a patient with concomitant motor neuron disease

Monsieurs, Koenraad G.; Broeckhoven, Christine Van; Martin, Jean‐Jacques; Dehaene, Ides; Heytens, L.

doi:10.1016/0022-510x(96)00034-2

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MH reactions can become apparent in PACU and, where trigger agents have been involved, all events with one exception 23 have developed within one hour of transfer to PACU [24][25][26][27] . Reported reactions following trigger-free anaesthesia are few and in general, mild [4][5][6][28][29][30][31][32][33] . Time of onset is more variable and no fatalities have been reported from these reactions.…”

Section: Discussionmentioning

confidence: 99%

Safe Duration of Postoperative Monitoring for Malignant Hyperthermia Susceptible Patients

Pollock

Langtont

Stowell

et al. 2004

Anaesth Intensive Care

View full text Add to dashboard Cite

Postoperative management of malignant hyperthermia (MH) susceptible patients has changed substantially over the last 20 years, with many patients now managed as day cases. Our previous policy was to monitor known MH susceptible patients (and relatives of known MH susceptible individuals not yet investigated by muscle biopsy) for four hours in the Post Anaesthetic Care Unit. However, anaesthetic literature reports suggest that MH reactions usually commence within one hour of anaesthesia. For this reason we conducted a retrospective review of Post Anaesthetic Care Unit data in 254 MH susceptible/related patients treated between 1991 and late 2000. On the basis of this review we instituted a policy change and reduced our monitoring time to one hour in the Post Anaesthetic Care Unit with a further 1.5 h in a step-down unit if indicated. A prospective study in a further 68 MH susceptible/related patients showed that no MH reactions were missed due to the shorter monitoring period.

show abstract

Section: Discussionmentioning

confidence: 99%

Safe Duration of Postoperative Monitoring for Malignant Hyperthermia Susceptible Patients

Pollock

Langtont

Stowell

et al. 2004

Anaesth Intensive Care

View full text Add to dashboard Cite

show abstract

Gly341Arg mutation indicating malignant hyperthermia susceptibility:

Monsieurs

Broeckhoven

Martin

et al. 1998

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Presence of Two Different Genetic Traits in Malignant Hyperthermia Families

Monnier¹,

Krivosic-Horber²,

Payen³

et al. 2002

Anesthesiology

180

View full text Add to dashboard Cite

Based on genetic and diagnostic test data, more than one MHS allele associated with the MHS phenotype was evidenced in four families. These data should be considered in view of the use of genetics for the diagnosis of MHS and when reaching conclusions of genetic heterogeneity in MHS families. Taking into account the usual dominant mode of transmission of MHS and the size of the investigated population, the authors propose an evaluation of the incidence of the MHS in the general population based on genetic data.

show abstract

Malignant hyperthermia susceptibility in a patient with concomitant motor neuron disease

Cited by 4 publications

References 7 publications

Safe Duration of Postoperative Monitoring for Malignant Hyperthermia Susceptible Patients

Safe Duration of Postoperative Monitoring for Malignant Hyperthermia Susceptible Patients

Gly341Arg mutation indicating malignant hyperthermia susceptibility:

Presence of Two Different Genetic Traits in Malignant Hyperthermia Families

Contact Info

Product

Resources

About